Tin tức & Cập nhật
Lọc theo Chuyên ngành:
OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies
05 Mar 2024
bởiAudrey Abella
Omalizumab scores in the NIH*-sponsored phase III OUtMATCH** trial, increasing the threshold for an allergic reaction to peanut and other common food allergens in children and adults with multiple food allergies.
OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies
05 Mar 2024Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
01 Mar 2024
bởiStephen Padilla
First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.